Roche Bobois Group is a high-end luxury furniture brand operator headquartered in Paris, France, and listed on Euronext Paris. Specializing in luxury indoor/outdoor furniture, home accessories, and design services, it leverages authentic French design, exquisite craftsmanship, and a direct-to-retail model, operating in 45 countries globally. With approximately 260 brand galleries and 1,200 employe
FranceEst. 19601.2K+Euronext Paris：RBO
Business Nature
Global Biopharmaceutical and Diagnostics Company:
• In-house R&D + In-house Manufacturing + Global Operations
• Global Supply Chain + Comprehensive Production System
• Innovation-Driven + Personalized Healthcare Solutions
• Vertical Integration + Pharmaceutical-Diagnostics Synergy
Core Business Revenue Breakdown
Business Segment | Revenue Share | Sales | Global Position
Pharmaceutical Business | 75% | $49.9 billion | Absolute Leader
Diagnostics Business | 25% | $16.1 billion | Absolute Leader
Pharmaceutical Business Structure
Therapeutic Area | Revenue Share | Sales | Growth Performance
Oncology | 50% | $25 billion | +9%
Immunology | 20% | $10 billion | +6%
Neuroscience | 15% | $7.5 billion | +8%
Other Areas | 15% | $7.4 billion | +4%
Detailed Financial Analysis 2023
Roche Group Overall Financial Performance
Financial Metric | 2023 Data | YoY Growth
Total Revenue | $66 billion | +1% +7% at constant exchange rates
Operating Profit | $19.5 billion | -5%
Net Profit | $13.5 billion | -7%
R&D Investment | $16.1 billion | +3%
Earnings Per Share | CHF 20.45 | -5%
Business Performance Analysis
Pharmaceutical Business: New products drove growth +8%
Diagnostics Business: Base diagnostics declined -13%
New Products: CHF 5 billion in new incremental sales
Exchange Rate Impact:
# Roche Group - 2025 Fiscal Year Corporate Report Summary
## Company Overview
Roche Group (F. Hoffmann-La Roche AG) is a Switzerland-based global healthcare company with headquarters in Basel. The company operates through two core business segments: pharmaceuticals (70% of revenue) and diagnostics (30% of revenue). In the pharmaceutical sector, Roche specializes in innovative medicines for oncology, immunology, neuroscience, and rare diseases. Its diagnostics division provides in vitro diagnostics, tissue diagnostics, molecular diagnostics, and diabetes management solutions. The company operates 101,000 employees globally across 150+ countries, maintaining 15 pharmaceutical factories, 20 diagnostic manufacturing facilities, and 30 R&D centers worldwide.
## Financial Performance
For fiscal year 2025, Roche reported total revenue of approximately 63 billion Swiss francs, representing 5.5% year-over-year growth. Net profit reached approximately 12 billion Swiss francs (+6.8%), while the company invested 12 billion Swiss francs in R&D (19% of revenue). Operating cash flow strengthened to 15 billion Swiss francs. Geographically, North America contributed 40% of revenue, Europe 35%, Asia-Pacific 20%, and other emerging markets 5%. China alone represented approximately 8% of global revenue at around 5 billion Swiss francs.
## Innovation and Market Position
Roche maintains a leadership position in the global biopharmaceutical industry with a brand heat score of 910/1000. The company's innovation pipeline includes 140+ projects in development, supported by over 15,000 researchers and more
